Study of treatments for a specific scar-ring hair loss
Treatments studied
Part of Skin clinical trials.
This study looks at treatment results for central centrifugal cicatricial alopecia (CCCA), a type of hair loss that causes scarring and permanent hair loss. It will follow African-American women to see how well treatments work for different levels of severity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an African-American woman age 18 to 60
- Have a confirmed CCCA diagnosis (including a scalp biopsy proving it)
- Have CCCA severity between 1 and 4 (as measured by a clinical scale)
- Be able to be seen for treatment at the Wake Forest Baptist Health Dermatology outpatient clinic
- Have CCCA only: no other hair-loss conditions at the same time
- No certain recent scalp treatments (topicals in last 4 months; oral antibiotics within last year; more than two steroid shots to the scalp in last year)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests an “all LED” red light cap to treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss. If you’re a woman with confirmed CCCA at Stage II–III and stable treatment, the study may help see whether red light can improve your hair loss without changing your current plan.
This trial compares platelet-rich plasma (a treatment made from your own blood) to a placebo to see if it helps regrow hair in women with a specific type of scarring hair loss called central centrifugal cicatricial alopecia (CCCA), which often affects women of African descent.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.
This trial tests if a non-ablative laser can help treat scarring alopecia (a type of hair loss where follicles are replaced by scar tissue). Researchers will also study your hair follicles' genes to understand how the laser works. It may be an option if your hair loss has been stable for at least 3 months.
This trial tests an experimental tablet for teenagers with severe alopecia areata, a condition causing patchy hair loss. The treatment may help regrow hair with clearer information about safety and effectiveness.
Hear when a new Central Centrifugal Cicatricial Alopecia (CCCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.